|
First author | Publication year | Country | Population | Age (control vs. intervention) | Sample size (control vs. intervention) | Type of study | Type of intervention | Control group | Duration |
|
Fan et al. | 2013 | China | NAFLD + T2DM + obesity | 54.68 ± 12.14; 51.02 ± 10.10 | 68/49 | RCT | Exenatide | Metformin | 12 weeks |
|
Shao et al. | 2014 | China | NAFLD + T2DM | 42 ± 3.2; 43 ± 4.1 | 30/30 | RCT | Exenatide + insulin glargine | Insulin aspart + insulin glargine | 12 weeks |
|
Armstrong et al. | 2016 | UK | NASH with/without T2DM | 18–70 | 7/7 | Double-blind, randomized, placebo-controlled trial | Liraglutide | Placebo | 12 weeks |
|
Armstrong et al. | 2016 | UK | NASH with/without T2DM | 50 ± 12; 50 ± 11 | 22/23 | Multicentre, double-blinded, randomized, placebo-controlled phase 2 trial | Liraglutide | Placebo | 48 weeks |
|
Khoo et al. | 2017 | Singapore | NAFLD + obesity | 43.7 ± 10.4; 39.0 ± 8.1 | 12/12 | Pilot randomized trial | Liraglutide | Diet + exercise | 26 weeks |
|
Wang et al. | 2017 | China | NAFLD + T2DM | 40–78; 41–75 | 49/49 | RCT | Exenatide + metformin | Metformin | 12 weeks |
|
Feng et al. | 2017 | China | NAFLD + T2DM | 48.07 ± 12.59; 46.79 ± 9.68 | 29/14.5 | Single-center, open-label, prospective, and randomized trial with parallel design | Liraglutide | Gliclazide | 24 weeks |
|
Feng et al. | 2017 | China | NAFLD + T2DM | 46.31 ± 12.32; 46.79 ± 9.68 | 29/14.5 | Single-center, open-label, prospective, and randomized trial with parallel design | Liraglutide | Metformin | 24 weeks |
|
Tian et al. | 2018 | China | NAFLD + T2DM | 56.4 ± 8.4; 58.5 ± 7.6 | 75/52 | RCT | Liraglutide | Metformin | 12 weeks |
|
Yan et al. | 2019 | China | NAFLD + T2DM | 45.7 ± 9.2; 43.1 ± 9.7 | 27/12 | Randomized, open-label, active-controlled, parallel-group, multicenter trial | Liraglutide | Sitagliptin | 26 weeks |
|
Yan et al. | 2019 | China | NAFLD + T2DM | 45.6 ± 7.6; 43.1 ± 9.7 | 24/12 | Randomized, open-label, active-controlled, parallel-group, multicenter trial | Liraglutide | Insulin glargine + metformin | 26 weeks |
|
Khoo et al. | 2019 | Singapore | NAFLD | 43.6 ± 9.9; 38.6 ± 8.2 | 15/15 | Prospective randomized pilot study | Liraglutide | Diet + exercise | 26 weeks |
|